Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT05501054 |
| Title | Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma. |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase Ib/II |
| Variant Requirements | No |
| Sponsors | M.D. Anderson Cancer Center |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Duke Cancer Institute | RECRUITING | Durham | North Carolina | 27710 | United States | Details |
| Abramson Cancer Center of the University of Pennsylvania | ACTIVE_NOT_RECRUITING | Philadelphia | Pennsylvania | 19104 | United States | Details |
| M D Anderson Cancer Center | RECRUITING | Houston | Texas | 77030 | United States | Details |